Governmental or Regulatory Activity
Makary Sails Through Senate Confirmation Hearing for FDA Commissioner
Martin Makary, FDA, Senate confirmation hearing, vaccine advisory committee, drug reviews, ethics, staffing changes
Drug Pricing and the Uncertain Future of the IRA Under Trump
IRA, Transplant Registry Unified Management Program, drug price, Medicare, Mediation, repeal, Changing, Uncertainty, Prices
Congressional Healthcare Reform Priorities Under Trump’s Second Term
ACA repeal, Medicaid block grants, price transparency, Medicare Advantage, drug pricing, value-based care
Trump Imposes New Tariffs on Canada, Mexico, and China; Medical Industry Seeks Exemptions
Trump tariffs, Canada, Mexico, China, medical technology exemptions, trade policy, national security, fentanyl crisis, illegal immigration
Senate Grills RFK Jr. on Controversial Health Stances in Contentious HHS Secretary Confirmation Hearings
Robert F. Kennedy Jr., HHS Secretary nomination, Senate confirmation hearings, vaccine skepticism, chronic disease focus, public health policy, Trump administration
FDA Postpones Opioids Advisory Committee Meeting and Cancels Kidney Drug Review
FDA, advisory committee, postponement, cancellation, opioids, kidney drug, regulatory meetings
FDA Delays Decision on Stealth BioTherapeutics’ Elamipretide for Barth Syndrome Until April 2025
Barth Syndrome, Elamipretide, FDA Decision, Stealth BioTherapeutics, Drug Approval Delay
Trump Revokes Biden’s Executive Order on AI Safety and Trustworthiness
AI Safety, Biden Executive Order, Trump Administration, Artificial Intelligence Governance, AI Regulation
InnoCare and KeyMed Secure $520M Licensing Deal for Bispecific Antibody with RTW-Built Biotech
InnoCare, KeyMed, Bispecific Antibody, RTW Investments, Licensing Deal, $520M
Medicare Selects Ozempic, Wegovy for Price Negotiations: A Step Towards Lowering Prescription Drug Costs
Medicare, drug price negotiations, Ozempic, Wegovy, Inflation Reduction Act, prescription drug costs, seniors, healthcare.